{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T18:10:16Z","timestamp":1741543816216,"version":"3.38.0"},"reference-count":41,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1461,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1111\/j.1532-849x.2011.00738.x","type":"journal-article","created":{"date-parts":[[2011,9,2]],"date-time":"2011-09-02T04:00:57Z","timestamp":1314936057000},"page":"601-603","source":"Crossref","is-referenced-by-count":6,"title":["Bisphosphonate Therapy for Skeletal Malignancies and Metastases: Impact on Jaw Bones and Prosthodontic Concerns"],"prefix":"10.1111","volume":"20","author":[{"given":"Arvind","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumyendra V.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Kumar Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronauk","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,1]]},"reference":[{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1601-0825.2002.01829.x","article-title":"Regulatory mechanisms of osteoblast and osteoclast differentiation","volume":"8","author":"Katagiri","year":"2002","journal-title":"Oral Dis"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","article-title":"The RANK\/RANKL\/OPG triad in cancer-induced bone diseases","volume":"25","author":"Dougall","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB7|cit7","first-page":"9","article-title":"Bone biology and the role of the RANK ligand pathway","volume":"23","author":"Murthy","year":"2009","journal-title":"Oncology(Williston Park)"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y","article-title":"Molecular mechanism of osteolytic bone metastases","volume":"88","author":"Guise","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-008-0085-3","article-title":"Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model","volume":"116","author":"Eck","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2009.01.011","article-title":"Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related factors","volume":"283","author":"Fili","year":"2009","journal-title":"Cancer Let"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","article-title":"Bisphosphonates: pharmacology and use in treatment of tumor-induced hypercalcaemia and metastatic bone disease","volume":"42","author":"Fleisch","year":"1991","journal-title":"Drugs"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB13|cit13","first-page":"2009","article-title":"Bisphosphonates as anti-cancer drugs","volume":"8","author":"Mundy","year":"1999","journal-title":"Drugs"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"ii91-ii95","DOI":"10.1093\/annonc\/mdj935","article-title":"Bisphosphonates and metastatic bone disease","volume":"17","author":"Barni","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1191\/0269216303pm800ra","article-title":"The use of Zoledronic acid in the management of metastatic bone disease and hypercalcaemia","volume":"17","author":"Neville-Webbe","year":"2003","journal-title":"Palliat Med"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB16|cit16","first-page":"456","article-title":"Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005","volume":"11","author":"Estefan\u00eda","year":"2006","journal-title":"Med Oral Pathol Oral Cir Buccal"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MOO.0b013e328304b445","article-title":"Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare","volume":"16","author":"Gevorgyan","year":"2008","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11926-008-0018-5","article-title":"Osteonecrosis of the jaw","volume":"10","author":"Sambrook","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.joms.2008.12.007","article-title":"Reconstruction of jaw defects caused by bisphosphonate induced osteonecrosis of jaws","volume":"67","author":"Marx","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate related osteonecrosis of the jaw: so many hypotheses so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.joms.2008.01.038","article-title":"Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment","volume":"66","author":"Allen","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","article-title":"A review of literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics","volume":"29","author":"Pazianas","year":"2007","journal-title":"Clin Ther"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/med.1011","article-title":"Centchroman, a selective estrogen receptor modulator, as contraceptive, and in the management of hormone-related clinical disorders","volume":"21","author":"Singh","year":"2001","journal-title":"Med Res Rev"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CIA.S6083","article-title":"Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on Lasofoxifene","volume":"5","author":"Gennari","year":"2010","journal-title":"Clin Interv Aging"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3565(24)38923-2","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action","volume":"295","author":"Deutertre","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00002512-200724050-00002","article-title":"Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development","volume":"2495","author":"Gennari","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/BOR.0b013e32832ca447","article-title":"New selective estrogen and androgen receptor modulators","volume":"21","author":"Clarke","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB29|cit29","first-page":"85","article-title":"Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies","volume":"14","author":"Maeda","year":"2004","journal-title":"Clin Calcium"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMoa0808692","article-title":"PEARL study investigators: lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/BOR.0b013e32832ca41c","article-title":"Denosumab update","volume":"21","author":"Lewiecki","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB32|cit32","first-page":"1","article-title":"Molecular mechanism and potential targets for bone metastasis","volume":"34","author":"Iguchi","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of Denosumab on bone mineral density in women receiving adjuvant aromatic inhibitors for non-metastatic breast cancer: subgroup analysis of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2174\/156800909789760375","article-title":"Denosumab: an era of target therapies in bone metastatic diseases","volume":"9","author":"Santini","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB35|cit35","first-page":"CD005326","article-title":"Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database","volume":"3","author":"O\u2019Donnell","year":"2006","journal-title":"Syst Rev"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/ciia.2006.1.4.367","article-title":"Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficiency","volume":"1","author":"Blake","year":"2006","journal-title":"Clin Interv Aging"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ncprheum1027","article-title":"Potential new drug targets for osteoporosis","volume":"5","author":"Deal","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/BOR.0b013e32832cbc2a","article-title":"Future therapeutic targets in osteoporosis","volume":"21","author":"Deal","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of Teriparatide on bone mineral density (BMD) after treatment with Raloxifene or Alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bmcl.2008.12.064","article-title":"Osteogenic activity of constituents from Butea monosperma","volume":"19","author":"Maurya","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1532-849X.2011.00738.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.addr.2004.12.014","article-title":"Targeting of the therapeutic agents to bone to treat metastatic cancer","volume":"57","author":"Bagi","year":"2005","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Journal of Prosthodontics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-849X.2011.00738.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1532-849X.2011.00738.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T17:51:50Z","timestamp":1741542710000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-849X.2011.00738.x"}},"subtitle":["Bisphosphonate Therapy for Malignancies"],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1532-849x.2011.00738.x","relation":{},"ISSN":["1059-941X"],"issn-type":[{"type":"print","value":"1059-941X"}],"subject":[],"published":{"date-parts":[[2011,9,1]]}}}